Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Late-Stage Pipeline

14%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 1
8(57.1%)
Phase 2
4(28.6%)
Phase 3
2(14.3%)
14Total
Phase 1(8)
Phase 2(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials
NCT06281964Phase 3Enrolling By Invitation

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Role: lead

NCT07538804Phase 1Not Yet Recruiting

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Role: lead

NCT06307795Phase 1Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT06328439Phase 1Active Not Recruiting

A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT07336732Phase 2Recruiting

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Role: lead

NCT06716138Phase 1Recruiting

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT07285148Phase 1Not Yet Recruiting

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Role: collaborator

NCT06574347Phase 2Recruiting

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Role: lead

NCT06970782Phase 3Not Yet Recruiting

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Role: lead

NCT06343064Phase 1Recruiting

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Role: lead

NCT06046495Phase 1Recruiting

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Role: lead

NCT06015503Phase 2Recruiting

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

Role: lead

NCT06827145Phase 2Active Not Recruiting

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Role: collaborator

NCT05347628Phase 1Unknown

Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Role: lead

All 14 trials loaded